查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球呼吸道感染市场 (2022-2030)：增长、未来展望、竞争对手分析
市场调查报告书
商品编码
1182411

全球呼吸道感染市场 (2022-2030)：增长、未来展望、竞争对手分析

Respiratory Tract Infection Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

呼吸道疾病患病率上升、气候不断变化、空气污染加剧、对保持个人卫生的日益重视等因素正在推动呼吸道感染药物市场的增长。

按地区划分，北美在2021年的规模最大。 这种增长主要归因于诸如患有呼吸系统并发症的大量人口、保持个人卫生的倾向以及有利的报销方案等因素。 与此同时，欧洲地区有望成为第二大市场，原因是天气凉爽、潮湿，而且治疗呼吸道感染的药物获得了监管部门的批准。

在本报告中，我们调查了全球呼吸道感染药物市场，提供了市场概况，分析了影响市场增长、转型和市场规模预测的各种因素，总结了细分市场、主要公司概况等。

内容

第一章前言

第 2 章执行摘要

第 3 章呼吸道感染市场：竞争分析

  • 供应商在市场中的地位
  • 供应商招聘策略
  • 主要行业战略
  • 等级分析：2021/2030

第 4 章呼吸道感染药物市场：宏观分析和市场动态

  • 世界市场规模：2020-2030
  • 市场动态
    • 市场驱动因素
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和製约因素的影响分析
  • 跷跷板分析

第 5 章呼吸道感染市场：按疾病分类

  • 市场概览
  • 增长/利润分析：2021/2030
  • 市场分类
    • 上呼吸道感染
    • 下呼吸道感染
    • 哮喘
    • RS病毒

第 6 章呼吸道感染市场：按药物分类

  • 市场概览
  • 增长/利润分析：2021/2030
  • 市场分类
    • 抗生素
    • 非甾体抗炎药 (NSAID)
    • 止咳药
    • 鼻减充血剂
    • 其他

第 7 章北美呼吸道感染市场

  • 市场概览
  • 呼吸道感染市场：按疾病分类
  • 呼吸道感染药物市场：按药物分类
  • 呼吸道感染药物市场：按地区

第 8 章英国和欧盟呼吸道感染市场

  • 市场概览
  • 呼吸道感染市场：按疾病分类
  • 呼吸道感染药物市场：按药物分类
  • 呼吸道感染药物市场：按地区

第 9 章亚太地区呼吸道感染市场

  • 市场概览
  • 呼吸道感染市场：按疾病分类
  • 呼吸道感染药物市场：按药物分类
  • 呼吸道感染药物市场：按地区

第 10 章：拉丁美洲呼吸道感染市场

  • 市场概览
  • 呼吸道感染市场：按疾病分类
  • 呼吸道感染药物市场：按药物分类
  • 呼吸道感染药物市场：按地区

第 11 章中东和非洲呼吸道感染市场

  • 市场概览
  • 呼吸道感染市场：按疾病分类
  • 呼吸道感染药物市场：按药物分类
  • 呼吸道感染药物市场：按地区

第12章公司简介

  • Abbott Laboratories
  • AstraZeneca
  • Abbvie Inc.
  • Boehringer Ingelheim GmbH
  • Cipla Pharmaceutical Company
  • GlaxoSmithkline plc
  • Pfizer Inc.
  • Merck & Co.
  • Novartis AG
  • F.Hoffman La Roche Ltd
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Theravence Biopharma
  • Vertex Pharmaceuticals Inc.
  • 其他
Product Code: 137543-08-22

This report on global respiratory tract infection treatment market studies various diseases and drug class. Rising prevalence of respiratory illness as per World Health Organization in 2015 three million deaths were recorded due to COPD, constantly changing climate, rising air pollution and increasing inclination to maintain personal hygiene are the drivers for the respiratory tract infection treatment market. The limiting factors related to this market are the rising incidence of antibiotic resistance and adverse events relating to the consumption of NSAIDs will hinder the growth of respiratory infection treatment market. Technological advancement in pharmacokinetics and drug screening for adverse events will result into deep market penetration. The increasing consumption of cheap generic medicines will hinder the branded drugs market. The drugs in the pipeline are Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead) and AZD7594, PT010 (AstraZeneca) etc.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global respiratory tract infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global respiratory tract infection treatment market. The key players profiled in this report are Abbott Laboratories, Abbvie Inc, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Novartis AG and others.

Respiratory Tract Infection Treatment Based on disease

Respiratory tract infection is one of the most common reason for the patients to visit the clinic or hospital. In base year 2021, Upper tract respiratory infection holds the largest market in the disease segment due to factors like, constant change in climate and rising air pollution, rising number of patients suffering with common cold as many types of viruses cause common cold, gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered face) and touching inanimate objects with contaminated hands. Lower respiratory tract infection will be the fastest growing market in the disease segment throughout the forecast period 2022-2030 chiefly due to factors such as rising number of air particulate matters which are exhumed by industrial chimneys and automobiles cause lower respiratory tract irritation and infection, on the basis of transmission it might be hospital acquired, ventilator acquired and community acquired. Technological advancement in the exact diagnosis of the causative agent in order to determine the treatment regimen for diseases like asthma, COPD and respiratory syncytial virus will be a positive factor for the fast growth of respiratory tract infection treatment market during the forecast period.

Respiratory Tract Infection Treatment Based on drug class

Respiratory tract infection treatment are having huge application due to factors such as rising prevalence of respiratory tract infections, constant change in climate, rising air pollution and increasing cases of antibiotics resistance. In base year 2021, Non-steroidal anti-inflammatory drugs (NSAIDS) holds the largest market in the drug treatment segment chiefly due to factors such as low cost, easy availability as OTC products, immediate symptomatic relief and technological advancement in the drug formulation e.g. micronized NSAIDs have desirable pharmacodynamics activity and early excretion rate to overcome NSAIDs adverse events. Antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period of 2022-2030 mainly due to factors such as its diverse application in various respiratory tract infections, improved pharmacokinetics to specifically target the respiratory tract infection for e.g. nebulized Aztreonam formulation is more effective than Aztreonam tablets, and technological advancement in the antibiotics resulting into next generation broad spectrum antibiotics e.g. methicillin formulated with branched polyethylenimine polymer to counteract antibiotic resistant cells. Overall, the global respiratory tract infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim GmbH, Pfizer, Inc., GlaxoSmithKline plc specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the market growth for respiratory tract infection treatment.

North America was observed as the largest market for respiratory tract infection treatment in the base year 2021. According to Centers for Disease Control and Prevention (CDC) American adults have 2 to 3 colds per year with underlying symptoms such as runny nose, sore throat, coughing, sneezing, headaches and body aches. The growth is attributed mainly due to large population suffering from respiratory complications and inclination to maintain personal hygiene along with favorable reimbursement scenario. Europe is expected to be the second largest market due to cool and damp weather favoring respiratory disease and regulatory approval for respiratory tract infection treatment products. Growth of Asia Pacific for respiratory tract infection treatment market is attributed by factors like rising prevalence of respiratory illness among huge population base, competitive market due to manufactures involved in respiratory tract infection treatment products, and impact of monsoon weather in the South Asian countries. However, factors such as developing health infrastructure, increasing disease awareness and increasing demand for respiratory tract infection treatment products are going to fuel the growth of respiratory tract infection treatment market in Latin America and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Respiratory Tract Infection Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Respiratory Tract Infection Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Disease

  • Upper respiratory tract infection
    • Common cold
    • Sinusitis
    • Epiglottitis
    • Laryngitis
  • Lower respiratory tract infection
    • Flu
    • Bronchitis
    • Pnuemonia
    • Chronic obstructive pulmonary disease (COPD)
  • Asthma
  • Respiratory syncytial virus

Drug

  • Antibiotics
    • Antibacterial
      • Cephalosporin (ceftriaxone, cefotaxime)
      • Penicillin antibiotic (amoxicillin, ampicillin)
      • B lactactamase inhibitors (sulbactum,clavulanic acid)
    • Antiviral
      • Ribavarin
      • Palivizumab
      • Ganciclovir
      • Vidarabine
  • Non-steroidal anti-inflammatory drug (NSAIDS)
    • Paracetamol
    • Ibuprofen
    • Naproxen
    • Aspirin
  • Cough suppresant
    • Dextromethorphan
    • Pholcodine
    • Benzonatate
    • Diphenhydramine
  • Nasal decongestant
    • Phenylephrine
    • Oxymetazoline
    • Pseudoephedrine
  • Others

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

  • Pre Covid-19 situation
  • Post Covid-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Respiratory Tract Infection Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Respiratory Tract Infection Treatment market?
  • Which is the largest regional market for Respiratory Tract Infection Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Respiratory Tract Infection Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Respiratory Tract Infection Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Respiratory Tract Infection Treatment Market
  • 2.2. Global Respiratory Tract Infection Treatment Market, By Disease, 2021 (US$ Million)
  • 2.3. Global Respiratory Tract Infection Treatment Market, By Drug, 2021 (US$ Million)
  • 2.4. Global Respiratory Tract Infection Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Respiratory Tract Infection Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Respiratory Tract Infection Treatment Market Vendors
  • 3.2. Strategies Adopted by Respiratory Tract Infection Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Respiratory Tract Infection Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Respiratory Tract Infection Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Upper respiratory tract infection
      • 5.3.1.1. Common cold
      • 5.3.1.2. Sinusitis
      • 5.3.1.3. Epiglottitis
      • 5.3.1.4. Laryngitis
    • 5.3.2. Lower respiratory tract infection
      • 5.3.2.1. Flu
      • 5.3.2.2. Bronchitis
      • 5.3.2.3. Pnuemonia
      • 5.3.2.4. Chronic obstructive pulmonary disease (COPD)
    • 5.3.3. Asthma
    • 5.3.4. Respiratory syncytial virus

6. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Antibiotics
      • 6.3.1.1. Antibacterial
        • 6.3.1.1.1. Cephalosporin (ceftriaxone, cefotaxime)
        • 6.3.1.1.2. Penicillin antibiotic (amoxicillin, ampicillin)
        • 6.3.1.1.3. B lactactamase inhibitors (sulbactum,clavulanic acid)
      • 6.3.1.2. Antiviral
        • 6.3.1.2.1. Ribavarin
        • 6.3.1.2.2. Palivizumab
        • 6.3.1.2.3. Ganciclovir
        • 6.3.1.2.4. Vidarabine
    • 6.3.2. Non-steroidal anti-inflammatory drug (NSAIDS)
      • 6.3.2.1. Paracetamol
      • 6.3.2.2. Ibuprofen
      • 6.3.2.3. Naproxen
      • 6.3.2.4. Aspirin
    • 6.3.3. Cough suppresant
      • 6.3.3.1. Dextromethorphan
      • 6.3.3.2. Pholcodine
      • 6.3.3.3. Benzonatate
      • 6.3.3.4. Diphenhydramine
    • 6.3.4. Nasal decongestant
      • 6.3.4.1. Phenylephrine
      • 6.3.4.2. Oxymetazoline
      • 6.3.4.3. Pseudoephedrine
    • 6.3.5. Others

7. North America Respiratory Tract Infection Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
  • 7.3. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
  • 7.4.Respiratory Tract Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 7.4.1.1.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 7.4.1.2.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 7.4.1.3.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

8. UK and European Union Respiratory Tract Infection Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
  • 8.3. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
  • 8.4.Respiratory Tract Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.1.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.2.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.3.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.4.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.5.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 8.4.1.6.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

9. Asia Pacific Respiratory Tract Infection Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
  • 9.3. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
  • 9.4.Respiratory Tract Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.1.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.2.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.3.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.4.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.5.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 9.4.1.6.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

10. Latin America Respiratory Tract Infection Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
  • 10.3. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
  • 10.4.Respiratory Tract Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 10.4.1.1.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 10.4.1.2.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 10.4.1.3.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

11. Middle East and Africa Respiratory Tract Infection Treatment Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
  • 11.3. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
  • 11.4.Respiratory Tract Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 11.4.1.1.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 11.4.1.2.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Respiratory Tract Infection Treatment Market: By Disease, 2020-2030, USD (Million)
        • 11.4.1.3.1. Respiratory Tract Infection Treatment Market: By Drug, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Abbott Laboratories
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. AstraZeneca
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Abbvie Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Boehringer Ingelheim GmbH
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Cipla Pharmaceutical Company
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. GlaxoSmithkline plc
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Merck & Co.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Novartis AG
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. F.Hoffman La Roche Ltd
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Sanofi
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Teva Pharmaceutical Industries Ltd.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. Theravence Biopharma
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
  • 12.14. Vertex Pharmaceuticals Inc.
    • 12.14.1. Company Overview
    • 12.14.2. Financial Performance
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Initiatives
  • 12.15. Others
    • 12.15.1. Company Overview
    • 12.15.2. Financial Performance
    • 12.15.3. Product Portfolio
    • 12.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 2 Global Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 3 Global Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 4 Global Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 Global Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 6 Global Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 7 Global Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 8 Global Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 9 Global Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 10 Global Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 11 North America Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 12 North America Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 13 North America Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 14 North America Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 15 North America Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 16 North America Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 17 North America Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 18 North America Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 19 North America Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 20 North America Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 21 U.S. Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 22 U.S. Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 23 U.S. Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 24 U.S. Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 25 U.S. Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 26 U.S. Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 27 U.S. Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 28 U.S. Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 29 U.S. Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 30 U.S. Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 31 Canada Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 32 Canada Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 33 Canada Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 34 Canada Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 35 Canada Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 36 Canada Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 37 Canada Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 38 Canada Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 39 Canada Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 40 Canada Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 41 Rest of North America Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 42 Rest of North America Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 43 Rest of North America Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 44 Rest of North America Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 45 Rest of North America Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 46 Rest of North America Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 47 Rest of North America Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 48 Rest of North America Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 49 Rest of North America Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 50 Rest of North America Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 51 UK and European Union Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 52 UK and European Union Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 53 UK and European Union Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 54 UK and European Union Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 55 UK and European Union Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 56 UK and European Union Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 57 UK and European Union Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 58 UK and European Union Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 59 UK and European Union Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 60 UK and European Union Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 61 UK Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 62 UK Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 63 UK Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 64 UK Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 65 UK Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 66 UK Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 67 UK Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 68 UK Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 69 UK Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 70 UK Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 71 Germany Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 72 Germany Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 73 Germany Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 74 Germany Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 75 Germany Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 76 Germany Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 77 Germany Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 78 Germany Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 79 Germany Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 80 Germany Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 81 Spain Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 82 Spain Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 83 Spain Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 84 Spain Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 85 Spain Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 86 Spain Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 87 Spain Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 88 Spain Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 89 Spain Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 90 Spain Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 91 Italy Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 92 Italy Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 93 Italy Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 94 Italy Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 95 Italy Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 96 Italy Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 97 Italy Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 98 Italy Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 99 Italy Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 100 Italy Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 101 France Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 102 France Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 103 France Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 104 France Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 105 France Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 106 France Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 107 France Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 108 France Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 109 France Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 110 France Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 111 Rest of Europe Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 112 Rest of Europe Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 113 Rest of Europe Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 114 Rest of Europe Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 115 Rest of Europe Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 116 Rest of Europe Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 117 Rest of Europe Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 118 Rest of Europe Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 119 Rest of Europe Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 120 Rest of Europe Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 121 Asia Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 122 Asia Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 123 Asia Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 124 Asia Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 125 Asia Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 126 Asia Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 127 Asia Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 128 Asia Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 129 Asia Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 130 Asia Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 131 China Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 132 China Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 133 China Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 134 China Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 135 China Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 136 China Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 137 China Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 138 China Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 139 China Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 140 China Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 141 Japan Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 142 Japan Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 143 Japan Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 144 Japan Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 145 Japan Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 146 Japan Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 147 Japan Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 148 Japan Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 149 Japan Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 150 Japan Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 151 India Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 152 India Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 153 India Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 154 India Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 155 India Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 156 India Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 157 India Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 158 India Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 159 India Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 160 India Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 161 Australia Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 162 Australia Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 163 Australia Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 164 Australia Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 165 Australia Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 166 Australia Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 167 Australia Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 168 Australia Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 169 Australia Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 170 Australia Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 171 South Korea Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 172 South Korea Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 173 South Korea Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 174 South Korea Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 175 South Korea Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 176 South Korea Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 177 South Korea Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 178 South Korea Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 179 South Korea Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 180 South Korea Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 181 Latin America Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 182 Latin America Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 183 Latin America Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 184 Latin America Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 185 Latin America Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 186 Latin America Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 187 Latin America Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 188 Latin America Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 189 Latin America Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 190 Latin America Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 191 Brazil Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 192 Brazil Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 193 Brazil Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 194 Brazil Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 195 Brazil Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 196 Brazil Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 197 Brazil Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 198 Brazil Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 199 Brazil Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 200 Brazil Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 201 Mexico Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 202 Mexico Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 203 Mexico Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 204 Mexico Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 205 Mexico Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 206 Mexico Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 207 Mexico Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 208 Mexico Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 209 Mexico Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 210 Mexico Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 211 Rest of Latin America Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 212 Rest of Latin America Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 213 Rest of Latin America Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 214 Rest of Latin America Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 215 Rest of Latin America Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 216 Rest of Latin America Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 217 Rest of Latin America Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 218 Rest of Latin America Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 219 Rest of Latin America Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 220 Rest of Latin America Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 221 Middle East and Africa Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 222 Middle East and Africa Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 223 Middle East and Africa Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 224 Middle East and Africa Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 225 Middle East and Africa Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 226 Middle East and Africa Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 227 Middle East and Africa Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 228 Middle East and Africa Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 229 Middle East and Africa Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 230 Middle East and Africa Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 231 GCC Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 232 GCC Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 233 GCC Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 234 GCC Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 235 GCC Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 236 GCC Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 237 GCC Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 238 GCC Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 239 GCC Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 240 GCC Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 241 Africa Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 242 Africa Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 243 Africa Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 244 Africa Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 245 Africa Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 246 Africa Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 247 Africa Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 248 Africa Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 249 Africa Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 250 Africa Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)
  • TABLE 251 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Disease, 2020-2030, USD (Million)
  • TABLE 252 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Upper respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 253 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Lower respiratory tract infection, 2020-2030, USD (Million)
  • TABLE 254 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 255 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Antibiotics, 2020-2030, USD (Million)
  • TABLE 256 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Antibacterial, 2020-2030, USD (Million)
  • TABLE 257 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Antiviral, 2020-2030, USD (Million)
  • TABLE 258 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Non-steroidal anti-inflammatory drug (NSAIDS), 2020-2030, USD (Million)
  • TABLE 259 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Cough suppresant, 2020-2030, USD (Million)
  • TABLE 260 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market By Nasal decongestant, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Respiratory Tract Infection Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Respiratory Tract Infection Treatment Market: Quality Assurance
  • FIG. 5 Global Respiratory Tract Infection Treatment Market, By Disease, 2021
  • FIG. 6 Global Respiratory Tract Infection Treatment Market, By Drug, 2021
  • FIG. 7 Global Respiratory Tract Infection Treatment Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Respiratory Tract Infection Treatment Market, 2021
  • FIG. 9 Market Positioning of Key Respiratory Tract Infection Treatment Market Players, 2021
  • FIG. 10 Global Respiratory Tract Infection Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Respiratory Tract Infection Treatment Market, By Disease, 2021 Vs 2030, %
  • FIG. 12 Global Respiratory Tract Infection Treatment Market, By Drug, 2021 Vs 2030, %
  • FIG. 13 U.S. Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 France Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 China Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 India Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market (US$ Million), 2020 - 2030